Peaston R T, Lennard T W, Lai L C
Department of Clinical Biochemistry, Freeman Group of Hospitals National Health Service Trust, Newcastle upon Tyne, United Kingdom.
J Clin Endocrinol Metab. 1996 Apr;81(4):1378-84. doi: 10.1210/jcem.81.4.8636337.
The detection and diagnosis of pheochromocytoma are highly dependent on the biochemical confirmation of excessive catecholamine release by the tumor. As the reliability of baseline plasma catecholamines in the detection of pheochromocytoma is questionable, assessment of the excretion rates of catecholamines or metabolites in 24-h urine collections remains the mainstay of initial biochemical investigation. However, diagnostic difficulties can arise from incomplete collection of 24-h specimens or equivocal increases in catecholamines due to stress. To investigate the diagnostic validity of shorter collection times for the biochemical detection of this tumor, we measured the excretion of catecholamines and metabolites after sleep, a period associated with decreased sympathetic activity. Overnight catecholamines, metanephrines, and 4-hydroxy-3-methoxymandelic acid (HMMA) levels were measured in 16 patients with histologically confirmed pheochromocytomas, 166 patients with hypertension, and 24 normotensive subjects. All measurements were performed by high performance liquid chromatography with electrochemical detection. Overnight excretion of norepinephrine in the tumor group (range, 86-1552 nmol/mmol creatinine) was significantly different (P <0.001) from that in the nontumor group (14-63 nmol/mmol creatinine). Autonomous secretion of norepinephrine was evident in all urine collections, including a patient with a predominantly epinephrine-secreting tumor. Overnight normetanephrine levels displayed a similar excretion pattern (P < 0.001), whereas overnight epinephrine and metanephrine levels were normal in 10 of the 16 patients with pheochromocytoma. In contrast, HMMA excretion in overnight urine collections was highly variable, with only 6 of the 16 patients in the tumor group having consistently elevated excretion. In the other 10 patients, overnight HMMA excretion showed a high intravariability. The measurement of catecholamines and total metanephrines after sleep is a viable approach for the exclusion of pheochromocytoma, as overnight urine collections completely differentiated patients with pheochromocytoma from hypertensive patients. Compared to 24-h results, overnight urinary norepinephrine levels provided a better diagnostic sensitivity and specificity (100% sensitivity and 98% specificity compared with 88% and 82%). Sleep urine samples simplify the collection protocol while avoiding the effects of stress and exercise.
嗜铬细胞瘤的检测与诊断高度依赖于肿瘤释放过量儿茶酚胺的生化确认。由于基线血浆儿茶酚胺在嗜铬细胞瘤检测中的可靠性存疑,24小时尿液中儿茶酚胺或代谢产物排泄率的评估仍是初始生化检查的主要手段。然而,24小时标本收集不完整或因应激导致儿茶酚胺出现模棱两可的升高可能会引发诊断困难。为了研究较短收集时间对该肿瘤生化检测的诊断有效性,我们测量了睡眠后儿茶酚胺和代谢产物的排泄情况,睡眠期交感神经活动会降低。对16例经组织学确诊的嗜铬细胞瘤患者、166例高血压患者和24例血压正常的受试者测量了夜间儿茶酚胺、甲氧基肾上腺素和4-羟基-3-甲氧基扁桃酸(HMMA)水平。所有测量均采用高效液相色谱电化学检测法。肿瘤组去甲肾上腺素的夜间排泄量(范围为86 - 1552 nmol/mmol肌酐)与非肿瘤组(14 - 63 nmol/mmol肌酐)有显著差异(P <0.001)。在所有尿液样本中均明显存在去甲肾上腺素的自主分泌,包括一名以分泌肾上腺素为主的肿瘤患者。夜间去甲变肾上腺素水平呈现类似的排泄模式(P <0.001),而16例嗜铬细胞瘤患者中有10例夜间肾上腺素和变肾上腺素水平正常。相比之下,夜间尿液中HMMA的排泄变化很大,肿瘤组16例患者中只有6例排泄量持续升高。在其他10例患者中,夜间HMMA排泄显示出高度的个体内变异性。睡眠后儿茶酚胺和总甲氧基肾上腺素的测量是排除嗜铬细胞瘤的可行方法,因为夜间尿液收集能将嗜铬细胞瘤患者与高血压患者完全区分开来。与24小时结果相比,夜间尿去甲肾上腺素水平提供了更好的诊断敏感性和特异性(敏感性为100%,特异性为98%,而24小时结果的敏感性和特异性分别为88%和82%)。睡眠尿液样本简化了收集流程,同时避免了应激和运动的影响。